Key Appointments Supervisory Board

IMMAGENE ANNOUNCES KEY APPOINTMENTS TO ITS SUPERVISORY BOARD

AMSTERDAM, DECEMBER 14, 2020

Immagene B.V., a private biotech company, announced today the appointment of Martine van Vugt and Allard Kaptein to the Supervisory Board. Martine and Allard will be joining Shobhit Dhawan (Oncode Oncology Bridge Fund) and Nicky Rijk-Vogels (Swanbridge Capital) on the Supervisory Board. Allard Kaptein will fulfill the role of chairperson of the Supervisory Board and advisor to the management board.

Maarten Ligtenberg, PhD, Chief Executive Officer of Immagene, said:

“We are delighted to welcome two accomplished biotech leaders to our supervisory board. Their insights and experience in drug discovery, drug development and business strategy will be incredibly valuable, as we continue to develop our platform of novel IO therapeutics to treat cancers. I look forward to working closely with both Martine and Allard, while we work on our first pipeline product.”

Martine van Vugt, PhD, is a senior Biopharma executive with 20 years of biotechnology industry experience. She is currently SVP, Chief of Staff at Genmab where she is responsible for Portfolio, Project and Alliance Management, as well as corporate strategic initiatives. She has been a linchpin in the success of Genmab as an inventor of Darzalex® and Tepezza, as well as through her role in Business Development in which she secured many partnerships and research deals for Genmab with big pharma/biotech companies. Martine holds an M.Sc. from the University of Wageningen and a Ph.D. from Utrecht University.

Commenting on her appointment as supervisory board director, next to advisor of Immagene, Martine said; “I am delighted to work with Immagene. Immagene’s approach of combining unique immuno-oncology insights with state of art small molecule development has the potential to create meaningful novel therapeutic approaches.” 

Allard Kaptein, PhD, is a serial biotech/pharma entrepreneur. Currently, he is managing director of Genase Therapeutics and entrepreneur in residence at Oncode Institute. Prior to that he was co-founder and EVP Discovery of Acerta Pharma, a NewCo that was started after spinning out, amongst others, the covalent BTK inhibitor series from MSD. This resulted in the FDA- and EMA approved drug acalabrutinib.

Allard has over 25 years’ experience in the pharmaceutical industry and is an expert in drug discovery and development, translating scientific concepts from the bench to the bedside.

Commenting on his appointment as supervisory board director, next to advisor of Immagene, Allard said; “Immagene is in a unique position to combine innovative drug targets from the great science done at the NKI with experience in drug discovery and development at Immagene. Combining these expertise opens the opportunity for the development of new and innovative treatment options for cancer patients. It is a privilege to be part of that.”